Novelion

NVLN-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about NVLN-T

Signal
Opinion
Expert
BUY
BUY
March 31, 2004
Great story. Shares are fully priced. Dont own
Show full opinionHide full opinion
Novelion (NVLN-T)
March 31, 2004
Great story. Shares are fully priced. Dont own
BUY WEAKNESS
BUY WEAKNESS
March 25, 2004
Likes the company, but is waiting for the price to pull back into the $20's before buying it again.
Show full opinionHide full opinion
Novelion (NVLN-T)
March 25, 2004
Likes the company, but is waiting for the price to pull back into the $20's before buying it again.
BUY
BUY
March 4, 2004
Have had drug developments that have been going a lot better for them. Prefers biotech companies that have a broader product mix. Market outlook seems to be quite positive for them.
Show full opinionHide full opinion
Novelion (NVLN-T)
March 4, 2004
Have had drug developments that have been going a lot better for them. Prefers biotech companies that have a broader product mix. Market outlook seems to be quite positive for them.
BUY
BUY
February 17, 2004
Visudine is approved for macular degeneration as well as ocular degeneration. Now making lots of money.
Show full opinionHide full opinion
Novelion (NVLN-T)
February 17, 2004
Visudine is approved for macular degeneration as well as ocular degeneration. Now making lots of money.
BUY
BUY
February 3, 2004
Own. Great technology. A lot to go. May have a bit of a pullback
Show full opinionHide full opinion
Novelion (NVLN-T)
February 3, 2004
Own. Great technology. A lot to go. May have a bit of a pullback
DON'T BUY
DON'T BUY
January 22, 2004
Have had difficulty in getting broad exposure of their products in the US. The jury is still out on whether this is a long-term efficacious treatment or not.
Show full opinionHide full opinion
Novelion (NVLN-T)
January 22, 2004
Have had difficulty in getting broad exposure of their products in the US. The jury is still out on whether this is a long-term efficacious treatment or not.
BUY
BUY
January 20, 2004
The long-term outlook should be good based on their product or vision health.
Show full opinionHide full opinion
Novelion (NVLN-T)
January 20, 2004
The long-term outlook should be good based on their product or vision health.
BUY WEAKNESS
BUY WEAKNESS
January 8, 2004
Thinks are still a little bit of upside. Potential for growth. Would buy on weakness.
Show full opinionHide full opinion
Novelion (NVLN-T)
January 8, 2004
Thinks are still a little bit of upside. Potential for growth. Would buy on weakness.
WEAK BUY
WEAK BUY
December 22, 2003
Expects the growth from visudine will be very strong. Buy for a three-year hold.
Show full opinionHide full opinion
Novelion (NVLN-T)
December 22, 2003
Expects the growth from visudine will be very strong. Buy for a three-year hold.
DON'T BUY
DON'T BUY
December 17, 2003
Model price is $24.83, so fully valued. Would consider at $21.40.
Show full opinionHide full opinion
Novelion (NVLN-T)
December 17, 2003
Model price is $24.83, so fully valued. Would consider at $21.40.
PAST TOP PICK
PAST TOP PICK
December 16, 2003
(A past top pick Sept 23/03. Up 5%.) Still likes. Has been volatile. Continue to believe in Visudine and the improved use of it.
Show full opinionHide full opinion
Novelion (NVLN-T)
December 16, 2003
(A past top pick Sept 23/03. Up 5%.) Still likes. Has been volatile. Continue to believe in Visudine and the improved use of it.
TOP PICK
TOP PICK
November 13, 2003
Suspects the price may mistakenly drop because of competitor coming out with a drug, but it will actually be used with QLT’s. Have had good earnings. The multiple in the high teens is really attractive. Have cash. Volatile
Show full opinionHide full opinion
Novelion (NVLN-T)
November 13, 2003
Suspects the price may mistakenly drop because of competitor coming out with a drug, but it will actually be used with QLT’s. Have had good earnings. The multiple in the high teens is really attractive. Have cash. Volatile
HOLD
HOLD
October 30, 2003
A very volatile stock. The caveat is that it is a one trick pony. Healthcare stocks have pulled back quite a bit.
Show full opinionHide full opinion
Novelion (NVLN-T)
October 30, 2003
A very volatile stock. The caveat is that it is a one trick pony. Healthcare stocks have pulled back quite a bit.
DON'T BUY
DON'T BUY
October 28, 2003
Have had good news recently in that their treatment for eye disease has been accepted by a number of US insurance companies. Probably fully priced now.
Show full opinionHide full opinion
Novelion (NVLN-T)
October 28, 2003
Have had good news recently in that their treatment for eye disease has been accepted by a number of US insurance companies. Probably fully priced now.
DON'T BUY
DON'T BUY
October 2, 2003
There have been a few negative developments this year. Fully valued.
Show full opinionHide full opinion
Novelion (NVLN-T)
October 2, 2003
There have been a few negative developments this year. Fully valued.
Showing 46 to 60 of 190 entries